🟡 Preliminary Evidence
Dexcom, Inc., the leading continuous glucose monitoring manufacturer, has notified the FDA of the theft of defective G7 sensor lots that were designated as scrap and intended for destruction. According to the company’s FDA notification, the company discovered the theft during routine quality and accounting reviews conducted in May 2026.
Key takeaways
- Stolen sensors were manufacturing rejects intended for destruction, not approved products
- Dexcom is conducting quality reviews and has notified potentially affected users
- The FDA has issued a safety alert regarding the compromised device security
Company Discovers Manufacturing Breach
DexCom, Inc. (Nasdaq: DXCM) announced on May 26, 2026, that ongoing quality and accounting reviews revealed the theft of specific G7 sensor lots originally designated as scrap material. According to the company’s FDA notification, these sensors were manufacturing rejects that failed quality control standards and were intended for destruction.
According to the FDA safety alert, the San Diego-based glucose biosensing leader has initiated comprehensive reviews of its manufacturing and disposal processes following the discovery.
FDA Issues Safety Alert for Compromised Devices
The Food and Drug Administration has issued a safety alert regarding the stolen Dexcom G7 sensors. According to the FDA notification, these particular sensor lots never received regulatory approval for patient use.
Patient Notification and Risk Assessment
According to the FDA safety alert, Dexcom has begun notifying potentially affected users who may have received sensors from the compromised lots. The company is working with healthcare providers to identify any patients who may have used the stolen devices and assess potential clinical impacts.
Quality and accounting reviews identified theft of G7 sensor lots designated as manufacturing scrap and intended for destruction
— DexCom, Inc. (FDA Safety Alert, May 2026)
What this means
Frequently asked questions
How can patients verify their G7 sensors are legitimate?
Contact your healthcare provider or Dexcom customer service to verify device lot numbers and authenticity. Legitimate sensors will have proper packaging and documentation from authorized distributors.
What risks do stolen defective sensors pose?
Manufacturing rejects may provide inaccurate glucose readings, potentially leading to inappropriate treatment decisions. These devices were rejected for failing quality standards and pose safety risks.
Should current G7 users be concerned?
Users of properly sourced G7 sensors from legitimate channels should continue normal use while verifying device authenticity with their healthcare provider if concerned.
The investigation into the Dexcom G7 sensor theft underscores the critical importance of secure medical device disposal and supply chain integrity.
Source: Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
